<!DOCTYPE html>
<html>
<head>
    <title>BREAKING: Federal Register: Tissue Agnostic Drug Development in Oncology; Draft Guidance for Industry; Availability</title>
    <meta charset="UTF-8">
    <style>
        body { font-family: Georgia, serif; max-width: 800px; margin: 0 auto; padding: 20px; }
        h1 { border-bottom: 2px solid #333; }
        .breaking { background: #fff3cd; border-left: 4px solid #dc3545; padding: 15px; }
        .source { background: #f8f9fa; padding: 10px; margin-top: 20px; font-size: 0.9em; }
        .timestamp { color: #666; }
    </style>
</head>
<body>
    <h1>BREAKING: Federal Register: Tissue Agnostic Drug Development in Oncology; Draft Guidance for Industry; Availability</h1>
    <p class="timestamp">Published: 2022-10-18 | Source: Federal Register</p>
    <div class="breaking">
        <p><strong>The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Tissue Agnostic Drug Development in Oncology." For the purpose of this guidance, the term "tissue agnostic oncology drug" refers to a drug that targets a specific molecular alteration(s) (a kind of biomarker) across multiple cancer types as defined, for example by organ, tissue, or tumor type. This draft guidance describes the development of tissue agnostic drugs, scientific...</strong></p>
    </div>
    <h2>Document Details</h2>
    <p><strong>Document Type:</strong> Notice</p>
    <p><strong>Agency:</strong> Health and Human Services Department, Food and Drug Administration</p>
    <p><strong>Document Number:</strong> 2022-22616</p>
    <p><strong>Publication Date:</strong> 2022-10-18</p>
    <h2>Official Source</h2>
    <p>Read the full document at: <a href="https://www.federalregister.gov/documents/2022/10/18/2022-22616/tissue-agnostic-drug-development-in-oncology-draft-guidance-for-industry-availability">https://www.federalregister.gov/documents/2022/10/18/2022-22616/tissue-agnostic-drug-development-in-oncology-draft-guidance-for-industry-availability</a></p>
    <div class="source"><strong>Source:</strong> Federal Register - 2022-22616</div>
    <p><a href="index.html">Back to Breaking News Wire</a></p>
</body>
</html>
